無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
SALE
市場調査レポート

注意欠陥多動性障害(ADHD) - 市場の洞察、疫学、市場予測 〜2027年

Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027

発行 DelveInsight Business Research LLP 商品コード 602034
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.50円で換算しております。
Back to Top
注意欠陥多動性障害(ADHD) - 市場の洞察、疫学、市場予測 〜2027年 Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027
出版日: 2018年12月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の注意欠陥多動性障害(ADHD)市場について調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、主要7カ国の市場動向、疫学的予測、アンメットニーズ、治療薬別の市場規模の推移の予測、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 レポート概要

第2章 注意欠陥多動性障害(ADHD)の市場概要

  • 主要7カ国の市場規模(実績値)
  • 主要7カ国の市場規模(予測値)

第3章 疾患背景と概要

  • イントロダクション
  • 原因
  • 病態生理
  • 症状
  • リスク因子
  • 診断

第4章 疫学と患者人口

  • 前提と根拠
  • 主要7カ国の有病数(実数・予測数)
  • 主要7カ国の有病数:年代別(実数・予測数)
  • 診断数と治療可能な症例数(実数・予測数)
  • 疾病の疫学:国別
  • 米国
    • 有病数(実数・予測数)
    • 有病数:年代別(実数・予測数)
    • 治療可能な症例数(実数・予測数)
  • 欧州5カ国
    • ドイツ
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • フランス
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • イタリア
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • スペイン
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • 英国
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
  • 日本
    • 有病数(実数・予測数)
    • 有病数:年代別(実数・予測数)
    • 治療可能な症例数(実数・予測数)

第5章 治療法

  • 治療アルゴリズム
  • 治療ガイドライン

第6章 上市済み薬

  • ストラテラ(Strattera):Eli Lilly
    • 製品説明
    • 作用機序
    • 規制のマイルストーン
    • 開発活動
    • 安全性と有効性
  • ヴィヴァンゼ(Vyvanse):Shire

第7章 新薬

  • キークロスコンテスト
  • Dasotraline:Sunovion
    • 規制のマイルストーン
    • 臨床開発
    • 製品プロファイル
    • 臨床パイプライン活動
  • ND0801:NeuroDerm

第8章 注意欠陥多動性障害(ADHD)市場規模

  • 主な所見
  • 主要7カ国市場の分析
  • 市場概要

第9章 主要7カ国市場の分析:国別

第10章 米国

  • 市場規模
  • 市場規模:治療薬別

第11章 ドイツ

  • 市場規模
  • 市場規模:治療薬別

第12章 フランス

  • 市場規模
  • 市場規模:治療薬別

第13章 英国

  • 市場規模
  • 市場規模:治療薬別

第14章 スペイン

  • 市場規模
  • 市場規模:治療薬別

第15章 イタリア

  • 市場規模
  • 市場規模:治療薬別

第16章 日本

  • 市場規模
  • 市場規模:治療薬別

第17章 市場の成長要因

第18章 市場の障壁

第19章 報告方法論

  • 利用した情報源

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Table 2 7MM Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Table 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Table 4 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Table 5 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Table 6 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Table 7 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Table 8 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Table 9 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Table 10 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Table 11 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Table 12 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Table 13 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Table 14 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Table 15 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Table 16 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Spain (2016-2027)

Table 17 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Table 18 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Table 19 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) the UK (2016-2027)

Table 20 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the UK (2016-2027)

Table 21 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the UK (2016-2027)

Table 22 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Table 23 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Table 24 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Table 25 Dasotraline, Clinical Trials by Recruitment status, 2018

Table 26 Dasotraline, Clinical Trials by Zone, 2018

Table 27 ND0801, Clinical Trials by Recruitment status, 2018

Table 28 ND0801, Clinical Trials by Zone, 2018

Table 29 Total 7 Major Market Size in USD, Million (2016-2027)

Table 30 Region wise Market Size in USD, Million (2016-2027)

Table 31 7MM-Market Size by Therapy in USD, Million (2016-2027)

Table 32 United States Market Size in USD, Million (2016-2027)

Table 33 United States Market Size by Therapy in USD, Million (2016-2027)

Table 34 Germany Market Size in USD, Million (2016-2027)

Table 35 Germany Market Size by Therapy in USD, Million (2016-2027)

Table 36 France Market Size in USD, Million (2016-2027)

Table 37 France Market Size by Therapy in USD, Million (2016-2027)

Table 38 Italy Market Size in USD, Million (2016-2027)

Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)

Table 40 Spain Market Size in USD, Million (2016-2027)

Table 41 Spain Market Size by Therapy in USD, Million (2016-2027)

Table 42 United Kingdom Market Size in USD, Million (2016-2027)

Table 43 United Kingdom Market Size by Therapy in USD, Million (2016-2027)

Table 44 Japan Market Size in USD, Million (2016-2027)

Table 45 Japan Market Size by Therapy in USD, Million (2016-2027)

List of Figures

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Figure 2 7MM Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Figure 5 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Figure 6 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Figure 8 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Figure 9 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)

Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Figure 11 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Figure 12 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)

Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Figure 14 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Figure 15 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)

Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Spain (2016-2027)

Figure 17 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Figure 18 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) the UK (2016-2027)

Figure 20 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the UK (2016-2027)

Figure 21 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in the UK (2016-2027)

Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Figure 23 Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Figure 24 Diagnosed and Treatable of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018

Figure 26 Dasotraline, Clinical Trials by Zone, 2018

Figure 27 ND0801, Clinical Trials by Recruitment status, 2018

Figure 28 ND0801, Clinical Trials by Zone, 2018

Figure 29 Total 7 Major Market Size in USD, Million (2016-2027)

Figure 30 Region wise Market Size in USD, Million (2016-2027)

Figure 31 7MM-Market Size by Therapy in USD, Million (2016-2027)

Figure 32 United States Market Size in USD, Million (2016-2027)

Figure 33 United States Market Size by Therapy in USD, Million (2016-2027)

Figure 34 Germany Market Size in USD, Million (2016-2027)

Figure 35 Germany Market Size by Therapy in USD, Million (2016-2027)

Figure 36 France Market Size in USD, Million (2016-2027)

Figure 37 France Market Size by Therapy in USD, Million (2016-2027)

Figure 38 Italy Market Size in USD, Million (2016-2027)

Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)

Figure 40 Spain Market Size in USD, Million (2016-2027)

Figure 41 Spain Market Size by Therapy in USD, Million (2016-2027)

Figure 42 United Kingdom Market Size in USD, Million (2016-2027)

Figure 43 United Kingdom Market Size by Therapy in USD, Million (2016-2027)

Figure 44 Japan Market Size in USD, Million (2016-2027)

Figure 45 Japan Market Size by Therapy in USD, Million (2016-2027)

目次
Product Code: DIMI0255

DelveInsight's Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder (ADHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder (ADHD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Attention Deficit Hyperactivity Disorder (ADHD) - Disease Understanding and Treatment Algorithm

According to American Psychiatric Association, Attention Deficit Hyperactivity Disorder (ADHD) is a brain/neurodevelopmental/neurobehavioral disorder and is one of the most common mental disorders affecting children. The disease also affects many adults. Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).

According to National Institute of Mental Health, Inattention and hyperactivity/impulsivity are the key behaviors of Attention Deficit Hyperactivity Disorder (ADHD). Some people with Attention Deficit Hyperactivity Disorder (ADHD) only have problems with one of the behaviors, while others have both inattention and hyperactivity-impulsivity. Most children have the combined type of Attention Deficit Hyperactivity Disorder (ADHD). ADHD is diagnosed as one of three types: inattentive type, hyperactive/impulsive type or combined type.

The DelveInsight Attention Deficit Hyperactivity Disorder (ADHD) market report gives the thorough understanding of the ADHD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Attention Deficit Hyperactivity Disorder (ADHD) in the US, Europe, and Japan.

Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology

The Attention Deficit Hyperactivity Disorder (ADHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalence of Attention Deficit Hyperactivity Disorder (ADHD), Age specific prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD), Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD)] scenario of Attention Deficit Hyperactivity Disorder (ADHD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to National Institute of Mental Health, the prevalence of children ever diagnosed with ADHD increased by 42% between 2003 (7.8%) and 2011 (11.0%).

As per National Comorbidity Survey-Adolescent Supplement (NCS-A), the lifetime prevalence of ADHD among U.S. adolescents aged 13 to 18 years was found to be 8.7%.

According to National Resource Center on ADHD, the estimates of worldwide adult ADHD prevalence averaged 3.4%.

According to ADHD Institute, meta-regression analyses have estimated the worldwide ADHD prevalence between 5.29% and 7.1% in children and adolescents, and at 3.4% (range 1.2-7.3%) in adults. The prevalence of Attention-deficit hyperactivity disorder (ADHD) is greater in males (60%) than females (40%).

Attention Deficit Hyperactivity Disorder (ADHD) Drug Chapters

This segment of the Attention Deficit Hyperactivity Disorder (ADHD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently available treatments can help reduce symptoms and improve functioning. Treatments include medications, psychotherapy, education or training, or a combination of treatments. The specific class of medications most commonly prescribed for Attention Deficit Hyperactivity Disorder (ADHD) include Stimulants. These Stimulant medications are found to be well-tolerated and they act quickly. Stimulant medications commonly prescribed for attention deficit disorder include methylphenidate (Ritalin, Concerta, Metadate, Methylin) and certain amphetamines (Dexedrine, Adderall etc.).

Other newer drugs approved for the treatment of Attention Deficit Disorder include Strattera (Eli Lilly) and Vyvanse (Shire). These drugs typically offer similar benefits to stimulants, but act in a different way on the brain. Antidepressants are also given in some cases. All these ADHD drugs however are related with certain side-effects such as decrease appetite, insomnia and decreased anxiety. Psychostimulants have also shown to be effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), but, their shorter duration of action highlights potential limitations.

Many players such as Sunovion, Orient Pharma, NeuroDerm and some other are involved in developing therapies for Attention Deficit Hyperactivity Disorder. Launch of emerging therapies such as Dasotraline (Sunovion) and ND0801 (NeuroDerm) etc. are expected to significantly change the treatment landscape of ADHD in the upcoming years.

Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

The Attention Deficit Hyperactivity Disorder (ADHD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Attention Deficit Hyperactivity Disorder (ADHD) in 7MM is expected to change from 2016-2027.

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Attention Deficit Hyperactivity Disorder (ADHD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Attention Deficit Hyperactivity Disorder (ADHD) Report Key Strengths

  • 10 Years Forecast
  • 7MMCoverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Attention Deficit Hyperactivity Disorder (ADHD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Attention Deficit Hyperactivity Disorder (ADHD) market
  • Organize sales and marketing efforts by identifying the best opportunities for Attention Deficit Hyperactivity Disorder (ADHD) market
  • To understand the future market competition in the Attention Deficit Hyperactivity Disorder (ADHD) market.

Table of Contents

1. Report Introduction

2. Attention Deficit Hyperactivity Disorder (ADHD) Market Overview at a Glance

  • 2.1. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2017
  • 2.2. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2027

3. Disease Background and Overview: Attention Deficit Hyperactivity Disorder (ADHD)

  • 3.1. Introduction
  • 3.2. Causes
  • 3.3. Pathophysiology
  • 3.4. Symptoms
  • 3.5. Risk Factor
  • 3.6. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Assumptions and Caveats
  • 4.2. 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
  • 4.3. 7MM Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
  • 4.4. 7MM Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
  • 4.5. Attention Deficit Hyperactivity Disorder (ADHD): Country- Wise Epidemiology
  • 4.6. United States
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)
    • 4.6.3. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)
    • 4.6.4. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)
  • 4.7. EU-5
  • 4.8. Assumptions and Rationale
  • 4.9. Germany
    • 4.9.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
    • 4.9.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)
    • 4.9.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in Germany (2016-2027)
  • 4.10. France
    • 4.10.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)
    • 4.10.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)
    • 4.10.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in France (2016-2027)
  • 4.11. Italy
    • 4.11.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)
    • 4.11.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)
    • 4.11.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in Italy (2016-2027)
  • 4.12. Spain
    • 4.12.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Spain (2016-2027)
    • 4.12.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Spain (2016-2027)
    • 4.12.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in Spain (2016-2027)
  • 4.13. United Kingdom
    • 4.13.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in UK (2016-2027)
    • 4.13.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in UK (2016-2027)
    • 4.13.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in UK (2016-2027)
  • 4.14. Japan
    • 4.14.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)
    • 4.14.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)
    • 4.14.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) in Japan (2016-2027)

5. Treatments & Medical Practices

  • 5.1. Treatment Algorithm
  • 5.2. Treatment Guidelines

6. Marketed drugs

  • 6.1. Strattera: Eli Lilly
    • 6.1.1. Product Description
    • 6.1.2. Mechanism of action
    • 6.1.3. Regulatory milestones
    • 6.1.4. Other Development Activities
    • 6.1.5. Safety and Efficacy
      • 6.1.5.1. Advantages and Disadvantages
      • 6.1.5.2. Product Profile
  • 6.2. Vyvanse: Shire
    • 6.2.1. Product Description
    • 6.2.2. Mechanism of action
    • 6.2.3. Regulatory milestones
    • 6.2.4. Other Development Activities
    • 6.2.5. Safety and Efficacy
      • 6.2.5.1. Advantages and Disadvantages
      • 6.2.5.2. Product Profile

7. Emerging Therapies

  • 7.1. Key Cross Competition
  • 7.2. Dasotraline: Sunovion
    • 7.2.1. Regulatory Milestones
    • 7.2.2. Clinical Development
    • 7.2.3. Product Profile
    • 7.2.4. Clinical Pipeline Activity
      • 7.2.4.1. Ongoing Trials Information
      • 7.2.4.2. Clinical Trial by Phase
  • 7.3. ND0801: NeuroDerm
    • 7.3.1. Regulatory Milestones
    • 7.3.2. Clinical Development
    • 7.3.3. Product Profile
    • 7.3.4. Clinical Pipeline Activity
      • 7.3.4.1. Ongoing Trials Information
      • 7.3.4.2. Clinical Trial by Phase

To be continued in report…

8. Attention Deficit Hyperactivity Disorder (ADHD) Market Size

  • 8.1. Key Findings
  • 8.2. Total 7MM Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis
  • 8.3. Overview of Total Attention Deficit Hyperactivity Disorder (ADHD) Market

9. 7MM Attention Deficit Hyperactivity Disorder (ADHD): Country-Wise Market Analysis

10. United States Market Size

  • 10.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 10.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

11. Germany Market Size

  • 11.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 11.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

12. France Market Size

  • 12.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 12.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

13. United Kingdom Market Size

  • 13.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 13.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

14. Spain Market Size

  • 14.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 14.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

15. Italy Market Size

  • 15.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 15.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

16. Japan Market Size

  • 16.1. Total Market Size of Attention Deficit Hyperactivity Disorder (ADHD)
  • 16.2. Market Size of Attention Deficit Hyperactivity Disorder (ADHD) by Therapy

17. Market Drivers

18. Market Barriers

19. Report Methodology

  • 19.1. Sources Used

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top